Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sinphar Pharmaceutical Co. Ltd. (1734.TW)
Yilan City, TW
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.31% | -0.16% | -2.06% | +0.16% | -0.96% | +1.48% | +0.29% | +8.83% | +10.89% | +37.25% | +128.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+7.0% Q1'26: +2.6% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+14.3% Q1'26: -37.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+10.6% Q1'26: +16.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+12.4% ★ Q1'26: +11.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+8.7% ★ Q1'26: +6.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+1.7% Q1'26: -3.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.25× Q1'26: 4.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.96B
est: 2.34B (+26.6%)
|
3.15B
est: 3.13B (+0.7%)
|
3.37B
est: 2.19B (+53.9%)
|
2.19B
2.19B – 2.19B
+0.0% YoY
|
2.19B
2.19B – 2.19B
-0.1% YoY
|
2.34B
2.34B – 2.34B
+6.9% YoY
|
3.13B
3.13B – 3.13B
+33.8% YoY
|
3.29B
3.29B – 3.29B
+5.0% YoY
|
3.46B
3.46B – 3.46B
+5.1% YoY
|
| EBITDA |
582.94M
est: 321.66M (+81.2%)
|
601.24M
est: 1.03B (-41.6%)
|
671.19M
est: 721.02M (-6.9%)
|
721.02M
721.02M – 721.02M
+0.0% YoY
|
720.03M
720.03M – 720.03M
-0.1% YoY
|
770.05M
770.05M – 770.05M
+6.9% YoY
|
1.03B
1.03B – 1.03B
+33.8% YoY
|
1.08B
1.08B – 1.08B
+5.0% YoY
|
1.14B
1.14B – 1.14B
+5.1% YoY
|
| EBIT |
339.42M
est: 100.40M (+238.1%)
|
343.87M
est: 891.30M (-61.4%)
|
416.86M
est: 623.91M (-33.2%)
|
623.91M
623.91M – 623.91M
+0.0% YoY
|
623.06M
623.06M – 623.06M
-0.1% YoY
|
666.34M
666.34M – 666.34M
+6.9% YoY
|
891.30M
891.30M – 891.30M
+33.8% YoY
|
936.01M
936.01M – 936.01M
+5.0% YoY
|
983.85M
983.85M – 983.85M
+5.1% YoY
|
| Net Income |
375.17M
est: 20.17M (+1,760.5%)
|
304.71M
est: 319.21M (-4.5%)
|
365.75M
est: 21.15M (+1,629.1%)
|
21.15M
21.15M – 21.15M
+0.0% YoY
|
13.02M
13.02M – 13.02M
-38.5% YoY
|
19.53M
19.53M – 19.53M
+50.0% YoY
|
304.01M
304.01M – 304.01M
+1,457.0% YoY
|
311.04M
311.04M – 311.04M
+2.3% YoY
|
383.09M
383.09M – 383.09M
+23.2% YoY
|
| SGA |
670.93M
est: 537.74M (+24.8%)
|
791.65M
est: 731.45M (+8.2%)
|
823.69M
est: 512.01M (+60.9%)
|
512.01M
512.01M – 512.01M
+0.0% YoY
|
511.31M
511.31M – 511.31M
-0.1% YoY
|
546.83M
546.83M – 546.83M
+6.9% YoY
|
731.45M
731.45M – 731.45M
+33.8% YoY
|
768.14M
768.14M – 768.14M
+5.0% YoY
|
807.40M
807.40M – 807.40M
+5.1% YoY
|
| EPS |
2.07
est: 0.11 (+1,763.0%)
|
1.68
est: 1.73 (-2.9%)
|
1.92
est: 0.11 (+1,574.8%)
|
0.11
0.11 – 0.11
+0.0% YoY
|
0.07
0.07 – 0.07
-38.5% YoY
|
0.11
0.11 – 0.11
+50.0% YoY
|
1.65
1.65 – 1.65
+1,457.0% YoY
|
1.69
1.69 – 1.69
+2.3% YoY
|
2.08
2.08 – 2.08
+23.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.02% | 3.24M | 0.07% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 89.8K | 0.65% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 58.8K | 0.46% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 3.5K | 0.42% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 197.9K | 0.39% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 10.9K | 0.44% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 119.2K | 0.28% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 88.4K | 0.29% |
| 9 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 1.2K | 0.33% |
| 10 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 1.1K | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhiwen Li | Founder & Chairman | 30M | male |
| Chih-Hsiao Chen | VP, CFO & Spokesperson | — | — |
| Hsin Huang Wen | Vice President and Chief R&D Officer | — | — |
| Qing Chen | Accountant | — | — |
| Youyang Bai | General Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1734.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
